GlassScriptPhysician profile
Steven P Unkel
NPI 1770544124
$10,991.70
in general payments reported to CMS, 2019-2025
52 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,586 · 2020: $962 · 2021: $1,545 · 2022: $1,626 · 2023: $1,711 · 2024: $1,920 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,174 · Education: $98.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,173.56 |
| Education | $98.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,153.69 | 2021-2025 | Vraylar, Avycaz, Teflaro |
| Astrazeneca Pharmaceuticals LP | $820.07 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $768.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $664.09 | 2019-2024 | |
| Alkermes, INC. | $604.39 | 2022-2025 | Lybalvi, Aristada |
| Bayer Healthcare Pharmaceuticals INC. | $601.00 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $446.49 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $422.17 | 2023-2025 | Rexulti, Nuedexta |
| Harmony Biosciences LLC | $401.68 | 2023-2025 | Wakix |
| Merck Sharp & Dohme LLC | $392.82 | 2019-2025 | Verquvo, Zerbaxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $388.34 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $351.81 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $321.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Axsome Therapeutics, INC. | $310.83 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $261.98 | 2020-2025 | Jardiance, Mounjaro |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Unkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.